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Introduction
Type I interferon (IFN) production is beneficial to the host 
organism due to its essential role in the innate immune 
response against invading pathogens, particularly viruses. 
Secreted type I IFNs (IFNα/β) bind to the IFNAR1/2 cell 
surface receptor, activating the IFN signaling pathway and 
expression of hundreds of IFN-stimulated genes (ISGs), 
many of which have antiviral activities.1 Type I IFNs also 
exert important immunomodulatory, antiproliferative, and 
antitumor activities. Regulation of type I IFN levels is criti-
cal, not only to optimize their beneficial activities but also 
to minimize the harmful effects caused by prolonged activa-
tion. Dysregulation of type I IFN production has been 
implicated in the pathogenesis of autoimmune and inflam-
matory diseases.2,3 More recently, an increasing number of 
type I interferonopathies have been identified, in which a 
genetic mutation results in detrimental upregulation of type 
I IFN expression.3,4 Chronic type I IFN signaling during 
persistent viral infections also results in immune dysfunc-
tion that can be detrimental to the host.5 Overall, type I IFN 
is beneficial to the host, although production must be tightly 
regulated to avoid harmful effects.
Induction of type I IFN is complex and has been exten-
sively reviewed.1,6,7 Briefly, type I IFN production occurs 
via multiple distinct routes and is dependent on the specific 
pathogen, the type of cell infected, and the stage of infec-
tion. Upon infection, pathogen-associated molecular pat-
terns (PAMPs) are recognized by a variety of host cell 
pattern recognition receptors (PRRs). Once stimulated by 
the appropriate PAMP, PRRs recruit an adaptor molecule 
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Abstract
Production of type I interferon (IFN) is an essential component of the innate immune response against invading pathogens. 
However, its production must be tightly regulated to avoid harmful effects. Compounds that modulate the IFN response are 
potentially valuable for a variety of applications due to IFN’s beneficial and detrimental roles. We developed and executed 
a cell-based high-throughput screen (HTS) targeting components that participate in and/or regulate the IRF3 and nuclear 
factor (NF)–κB branches of the IFN induction pathway. The assay detects activation of the IFN induction pathway via an 
enhanced green fluorescent protein (eGFP) reporter gene under the control of the IFNβ promoter and was optimized, 
miniaturized, and demonstrated suitable for HTS as robust Z′ factor scores of >0.6 were consistently achieved. A diversity 
screening set of 15,667 small molecules was assayed and two novel hit compounds validated that specifically inhibit the IFN 
induction pathway. We demonstrate that one of these compounds acts at or upstream of IRF3 phosphorylation. A second 
cell-based assay to detect activation of the IFN signaling (Jak-Stat) pathway via an eGFP reporter gene under the control 
of an IFN-stimulated response element (ISRE) containing MxA promoter also performed well (robust Z′ factor >0.7) and 
may therefore be similarly used to identify small molecules that modulate the IFN signaling pathway.
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that feeds into common downstream signaling pathways 
that result in the activation of key transcription factors 
(nuclear factor [NF]–κB and IRF3 or IRF7), which induce 
the expression of type I IFNs. A commonly used potent 
inducer of type I IFNs is the Sendai virus (SeV) Cantell 
strain, which is rich in defective interfering particles (DIs) 
that robustly activate the cytosolic PRR RIG-I.8,9 RIG-I 
recruits the adapter MAVS, which feeds into the IRF3 and 
NF-κB branches of the IFN induction pathway. During 
IRF3 activation, kinases TBK1 and IKKε phosphorylate 
IRF3, causing exposure of a nuclear localization signal to 
facilitate IRF3 nuclear translocation.1 During NF-κB acti-
vation, the IKK kinase complex activates IκB phosphoryla-
tion and degradation, allowing NF-κB nuclear migration.1,7 
Once in the nucleus, activated IRF3 and NF-κB cooperate, 
along with other transcription factors, to trigger optimal 
type I IFN expression.1,7
The IFN induction pathway involves many other compo-
nents, particularly regulatory factors,10 than those described 
above, and thus a wide variety of potential targets exists. 
Small molecules that modulate the IFN induction pathway 
would be useful as (1) chemical tools to further investigate 
the type I IFN induction pathway, (2) therapeutics to treat 
diseases caused by dysregulation of the type I IFN 
response,3,4 (3) treatment of viral diseases as either activa-
tors to exploit type I IFN antiviral properties11 or inhibitors 
to block the detrimental effects of immune dysfunction dur-
ing persistent viral infections,5 and (4) biotechnology appli-
cations (e.g., we recently demonstrated the utility of IFN 
inhibitors in the production of interferon-sensitive viruses 
for a range of applications).12
In this study, we developed a cell-based screen to iden-
tify novel compounds that modulate the IFN induction 
pathway. The assay detects activation of the IFN induction 
pathway via expression of enhanced green fluorescent pro-
tein (eGFP) under the control of the IFNβ promoter.12,13 IFN 
induction is activated by SeV (Cantell) infection; hence, 
compounds targeting the IRF3 or NF-κB branches of the 
IFN induction pathway have the potential to be identified. 
We conducted a high-throughput screen (HTS) and identi-
fied two novel inhibitors that specifically inhibit the IFN 
induction pathway.
Materials and Methods
Cell Lines, Sendai Virus, and IFN
The A549 cell-line (ECACC, Salisbury, UK) and deriva-
tives were maintained in Dulbecco’s modified Eagle’s 
medium with 10% (v/v) fetal bovine serum and L-glutamine 
(2 mM). A549 reporter cell line derivatives, A549/pr(IFNβ).
GFP and A549/pr(ISRE).GFP, contain an eGFP gene under 
the control of the IFNβ promoter or the MxA promoter 
(containing IFN-stimulated response elements [ISREs]), 
respectively.12,13 SeV Cantell (4000 HA U/mL) was pur-
chased from Charles River Laboratories (North Franklin, 
CT) and used at a 1:100 dilution unless otherwise stated. 
Purified IFNα (NHS, Dundee, UK) was used at 104 U/mL.
Inhibitors and Compound Library
Inhibitors of the IFN response, BX795,14 TPCA-1,15 and 
ruxolitinib (Rux)16 (Selleck Chemicals, Munich, Germany), 
were prepared as 10-mM stocks in DMSO. Actinomycin D 
(AMD) and cyclohexamide (CHX) (Sigma, Dorset, UK) 
were prepared as 10-mM stocks in DMSO and ethanol, 
respectively. The Small Diversity Set Compound Library 
(Dundee Drug Discovery Unit [DDU], University of 
Dundee, UK) was used for HTS and consists of 15,667 
compounds at 10 mM in DMSO. Hit compounds StA-IFN-1 
(4-(1-acetyl-1H-indol-3-yl)-5-methyl-2,4-dihydro-3H- 
pyrazol-3-one) (Chembridge, San Diego, CA), StA-IFN-2 
(4-{[4-(thieno[3,2-d]pyrimidin-4-yl)-1,4-diazepan-1-yl]
methyl}benzonitrile) (Enamine, Monmouth Jt., NJ), StA-
IFN-4 (2-[(4,5-dichloro-6-oxo-1(6H)-pyridazinyl)methyl]-
8-methyl-4H-pyrido[1,2-a]pyrimidin-4-one) (Enamine, 
Monmouth, NJ), and StA-IFN-5 (6-methyl-4-phenyl-N-
(pyridin-4-yl)quinazolin-2-amine) (Mcule, Budapest, 
Hungary) were stored as 10-mM stocks in DMSO. All com-
pounds were used at the indicated concentrations.
Cell-Based IFN Induction and IFN Signaling 
Reporter Assays
The A549/pr(IFNβ).GFP and A549/pr(ISRE).GFP reporter 
cell lines have previously been used to monitor the IFN 
induction and IFN signaling pathways, respectively.12 
Briefly, A549/pr(IFNβ).GFP cells were seeded (9 × 104 
cells/cm2) into 96-well plates and incubated overnight. 
A549/pr(IFNβ).GFP reporter cells were infected with SeV 
(40 HA U/mL) to induce the IFN induction pathway. Sixteen 
hours postinfection, cells were fixed with 5% (v/v) formal-
dehyde and washed prior to measuring eGFP expression 
using an Infinite M200 Pro (Tecan, Männedorf, Switzerland) 
plate reader at an excitation/emission of 488/518 nm. A549/
pr(ISRE).GFP cells were similarly seeded and incubated 
with purified IFNα (104 U/mL) to activate the IFN signaling 
pathway. Forty hours post-IFN, treatment cells were fixed 
and washed and eGFP expression monitored as above. 
When appropriate, cells were treated with compound 2 h 
prior to induction of the IFN induction or IFN signaling 
pathways. eGFP reporter gene expression was determined 
as either signal-to-background (S/B) ratio or percentage 
inhibition. S/B ratio was calculated using the GFP signal in 
raw fluorescent units (RFU) as
 RFU(Activated)/RFU(Unactivated) (1)
 at University of St Andrews on June 30, 2016jbx.sagepub.comDownloaded from 
Gage et al. 3
where activated represents SeV-infected cells and unacti-
vated is uninfected cells. Percentage inhibition was calcu-
lated using the RFU of each well normalized to a percentage 
effect (% effect) of the positive control, calculated as
                     % Effect = [(RFUActivated – RFUTest)/ 
                    (RFUActivated – RFUUnactivated)] * 100.    (2)
HTS and Dose-Response Assays
A single-point HTS using the DDU Small Diversity Set 
library in a 384-well format was performed using the A549/
pr(IFNβ).GFP reporter assay described above with the fol-
lowing variations. Cells were seeded (9 × 104 cells/cm2) 
into 384-well plates and 30 µM of compound added using 
an Echo 550 liquid handler (Labcyte, Sunnyvale, CA) 2 h 
prior to SeV infection. An EnVision (PerkinElmer, Waltham, 
MA) plate reader was used to measure eGFP expression at 
an excitation/emission of 485/535 nm. HTS data output was 
analyzed by the RFU of each well normalized to a % effect 
of the controls, calculated as detailed above for percentage 
inhibition. HTS quality control criteria for the acceptance of 
an assay plate are as follows: S/B ratio ≥2%, coefficient of 
variation <8% ((σ/µ)*100), and robust Z′ ≥0.5.
Robust Z′ factor was calculated with the following 
formula:
 (3)
with MAD = mean absolute deviation. Each statistical 
parameter was determined for each assay plate and the 
overall screen.
Ten-point dose-response assays were performed using 
the A549/pr(IFNβ).GFP and A549/pr(ISRE).GFP reporter 
assays and the Echo 550 liquid handler via a 10-point two-
fold serial dilution (50 to 0.1 µM) of hit compounds. For 
determination of potency, a four-parameter logistic fit of the 
following form was used:
 y = A + (B – A) / (1 + ((10C) / x)D), (4)
where A = % inhibition at bottom, B = % inhibition at top, 
C = 50% effect concentration (IC50), D = slope, x = inhibitor 
concentration, and y = % inhibition. ActivityBase XE 
(IDBS, Alameda, CA) was used for all data processing, 
with utilization of SARgen (IDBS) software.
Cell Viability Assays
The AlamarBlue (AB) reagent (Life Technologies, Carlsbad, 
CA) was used to assess the effect of test compounds on cell 
viability. Seeded A549 cells were treated with compounds 
using a 10-point twofold serial dilution (50 to 0.1 µM) and 
incubated for 48 h. AB was added to a final concentration of 
10% (v/v) and incubated for 4 h and fluorescence measured 
at an excitation/emission of 545/590 nm. The percentage 
reduction in AB was calculated using the following con-
trols: 0% reduced (DMEM + AB) and 100% reduced (Cells + 
DMEM + AB).
To assess compound effect on global cellular protein 
synthesis, cells were treated with compound for 24 and 48 h 
prior to labeling with [35S]Met/Cys pro-mix (PerkinElmer) 
for 1 h. To determine the effect of compound on SeV repli-
cation, cells were treated for 2 h followed by infection for 
18 h prior to labeling as above. Whole-cell lysates were 
separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by isotope incorpo-
ration visualization and quantification using a FLA-5000 
phosphoimager (FujiFilm, Tokyo, Japan) and Image Studio 
software (Li-Cor, Lincoln, NE).
Quantitative Reverse-Transcriptase PCR Assay
A quantitative reverse-transcriptase (qRT)–PCR assay deter-
mined compound effect on IFNβ and MxA gene transcript lev-
els upon stimulation of the IFN induction or IFN signaling 
pathways, respectively. A549 cells were treated with com-
pound (10 µM) 2 h prior to either SeV infection (4 h) or IFNα 
treatment (16 h). Total cellular RNA was extracted using 
phenol-chloroform separation with Trizol. Total messenger 
RNA (mRNA) was reverse transcribed using RevertAid 
reverse transcriptase and oligo d(T) primers (ThermoFisher 
Scientific, Perth, UK). Resultant complementary DNA 
(cDNA) was used to qPCR amplify IFNβ (forward primer: 
GCTTCTCCACTACAGCTCTTTC; reverse primer: CAGTA 
TTCAAGCCTCCCATTCA; nucleotides 40–155), MxA (for-
ward primer: GCCTGCTGACATTGGGTATAA; reverse 
primer: CCCTGAAATATGGGTGGTTCTC; nucleotides 570–
931), or actin (forward primer: GGCACCACACCTTCTA 
CAAT; reverse primer CCTTAATGTCACGCACGATTTC; 
nucleotides 257–640) using MESA Blue Mastermix 
(Eurogentec, Liege, Belgium) and an Mx3005P real-time PCR 
thermocycler (Stratagene, San Diego, CA). A standard curve 
was generated (5-point 10-fold serial dilution of DNA of 
known concentration) to facilitate absolute quantification 
using MxPro software (Stratagene). Actin was used to normal-
ize values with respect to cell number.
Immunoblotting and Immunofluorescence 
Microscopy
Immunoblotting was used to detect phosphorylated IRF3 
(pIRF3) and STAT1 (pSTAT1) in A549 cells following 
compound treatment (10 µM) and stimulation of the IFN 
induction or IFN signaling pathways, respectively. To detect 
1
3 1 4826
3 1 4826
−
( ) ( )( ) +* . *
* . *
MAD 0% inhibition raw data
MAD 100% inhibition raw data
MEDIAN 0% inhibition raw data
( ) ( )( )
( )  −
( ) MEDIAN 100% inhibition raw data
.
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pIRF3, cells were treated with compound 2 h prior to SeV 
infection. Three hours postinfection, cells were lysed and 
subjected to SDS-PAGE/Western blot, followed by immuno-
detection with rabbit anti-pIRF3 antibody (Cell Signaling, 
Danvers, MA) and goat anti-rabbit IRDye680 conjugated 
secondary antibody (Li-Cor). To detect pSTAT1, cells were 
treated with compound 2 h prior to incubation with purified 
IFNα. Fifteen minutes post-IFNα treatment, cell lysates were 
processed as above and pSTAT1 detected with goat anti-
pSTAT1 antibody (Santa Cruz, Heidelberg, Germany) and 
donkey anti-goat horseradish peroxidase (HRP)–conjugated 
secondary antibody (Santa Cruz). Actin was detected using 
mouse anti-actin antibody (Sigma, Dorset, UK) and goat 
anti-mouse IRDye800 conjugated secondary antibody 
(Li-Cor). Bands were visualized via an Odyssey CLx near-
infrared scanner (Li-Cor) or enhanced chemiluminescence.
Immunofluorescence microscopy was used to determine 
the effect of compounds on IRF3 nuclear translocation. To 
visualize IRF3 nuclear translocation, A549 cells were 
seeded onto coverslips, treated with compound, and infected 
with SeV. Three hours postinfection, cells were fixed, per-
meabilized, and incubated with rabbit anti-IRF3 antibody 
(Santa Cruz) followed by donkey anti-rabbit Texas Red 
conjugated secondary antibody (Abcam, Cambridge, UK) 
together with DAPI (Sigma). Images were collected on a 
Nikon Microphot-FXA microscope (Nikon, Surrey, UK) 
(40× magnification) and processed using ImageJ64 soft-
ware (ImageJ, NIH, Bethesda, MD).
Results
Development, Optimization, and Miniaturization 
of the A549/pr(IFNβ).GFP Reporter Assay to a 
Format Suitable for HTS
The A549/pr(IFNβ).GFP reporter cell line provides a 
straightforward method to detect activation of the IFN 
induction pathway via eGFP expression under the control of 
the IFNβ promoter following stimulation by virus infec-
tion.12,13 We previously used this A549/pr(IFNβ).GFP 
reporter assay to demonstrate that existing IFN inhibitors 
block the IFN induction pathway.12 We propose here that 
the A549/pr(IFNβ).GFP reporter assay can be used to iden-
tify novel compounds that modulate the IFN induction 
pathway.
To adapt our assay to a format suitable for HTS, we 
embarked on a program of assay optimization to maximize 
the S/B ratio and minimize the timescale. Variable parame-
ters were sequentially optimized (Suppl. Fig. S1), and the 
resultant assay achieved a maximum S/B ratio of 2.6 ± 0.06. 
We next evaluated the robustness of assay performance 
using robust Z′ factor17 alongside S/B ratio and coefficient 
of variation (CV) (Suppl. Table S1). In the first instance, a 
96-well plate format using activated and nonactivated 
A549/pr(IFNβ).GFP reporter cells was tested. The assay 
was then miniaturized to a 384-well plate format and a 
small-scale pilot screen (three plates) was performed using 
the DDU Small Diversity Set compound library. Overall, 
we demonstrate that the assay is robust, as a robust Z′ factor 
of ≥0.66 ± 0.03 was consistently achieved. We further veri-
fied our A549/pr(IFNβ).GFP reporter assay by demonstrat-
ing that two IFN induction pathway inhibitors, BX79514 
and TPCA-1,15 reduced eGFP expression in activated A549/
pr(IFNβ).GFP reporter cells in a dose-dependent manner 
(Suppl. Fig. S2). Overall, this provides proof of principle 
that our assay is suitable for use in diversity screening to 
identify compounds that modulate the IFN induction 
pathway.
Diversity Screening Using the A549/pr(IFNβ).
GFP Reporter Assay to Identify Compounds That 
Modulate the IFN Induction Pathway
The A549/pr(IFNβ).GFP reporter assay was used to per-
form a single-point primary HTS using the DDU Small 
Diversity Set library (n = 15,667 compounds). Screening 
was performed in four batches of 12 × 384-well plates 
(Fig. 1A). The primary screen achieved a robust Z′ factor 
of 0.61 ± 0.1, which was comparable to that achieved dur-
ing assay development, but the S/B ratio dropped to 1.6 ± 
0.2 (Fig. 1B). Maintenance of the robust Z′ factor score 
indicates that the assay remained robust. A normal distri-
bution of percentage effect was observed, centered at 0% 
to 10% inhibition, indicating that the screen performed as 
expected (Fig. 1C).
To be considered a hit, a compound was arbitrarily des-
ignated as having a percentage effect of greater than 50% or 
less than −50%, as well as 2 standard deviations above or 
below the test well average for the plate. Initially, these cri-
teria resulted in 264 putative compounds. Duplicated com-
pounds were withdrawn, followed by any compound that 
was shown to be toxic in previous DDU cell-based screens. 
This selection process reduced the number of hits to 245 
(200 inhibited and 45 enhanced eGFP expression), yielding 
a primary screen hit rate of 1.3%.
The 245 putative hits were taken forward to a secondary 
dose-response screen, which achieved a robust Z′ factor of 
0.8 ± 0.02 and S/B ratio of 3.6 ± 0.1 (Fig. 2A). The dose-
response curve for each compound was used to generate its 
IC50 value (Fig. 2B). Of the 245 hits tested, 109 were 
deemed inactive due to attaining an IC50 value greater than 
the highest concentration tested (50 µM) and were thus dis-
carded. This eliminated all hits that enhanced eGFP expres-
sion. The remaining confirmed hits inhibited eGFP 
expression in a dose-dependent manner, and 41 were 
deemed the most favorable as they attained an IC50 value of 
≤10 µM (Fig. 2B).
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The original 200 putative inhibitors identified in the pri-
mary HTS were also subject to a specificity screen using a 
second reporter cell line, A549/pr(ISRE).GFP, which 
detects activation of the IFN signaling pathway via expres-
sion of eGFP under the control of the ISRE-containing MxA 
promoter following stimulation with purified IFNα.12 For 
each of the putative 200 hits, a dose-response screen using 
the A549/pr(ISRE).GFP reporter assay was performed, 
which achieved a robust Z′ factor of 0.7 ± 0.07 and S/B ratio 
of 2.5 ± 0.1 (Fig. 2C). The IC50 values for each compound 
generated in the A549/pr(IFNβ).GFP and A549/pr(ISRE).
GFP reporter assays were plotted against each other (Fig. 
2D). Of the 200 hits tested, 35 hits exhibited possible dual 
activity as they attained IC50 values of ≤10 µM in both 
assays. More important, 83 exhibited no activity in the 
A549/pr(ISRE).GFP reporter assay, strongly suggesting 
that their activity is specific to inhibition of the IFN induc-
tion pathway. Six of these IFN induction pathway-specific 
hits had an IC50 value of ≤10 µM and hence were consid-
ered confirmed hits.
Validation of Hits That Specifically Inhibit the 
IFN Induction Pathway
The confirmed six hits were named StA-IFN-1, -2, -3, -4, 
-5, and -6. The hits were cherry picked from the com-
pound library and analyzed by liquid chromatography–mass 
spectrometry (LC-MS) to confirm their identity. StA-IFN-3 
and -6 failed LC-MS; hence, only StA-IFN-1, -2, -4, and -5 
were repurchased and their activity and specificity con-
firmed by retesting in the two reporter assays. StA-IFN-2 
and -5 were discontinued, as repurchased compound failed 
to exhibit pathway specificity (Suppl. Fig. S3). However, 
StA-IFN-1 and -4 (Fig. 3A,B) behaved as expected and 
were further examined by comparing their activity to the 
inhibitors TPCA-1, which inhibits the IFN induction path-
way component IKKβ,15 and ruxolitinib, which inhibits IFN 
signaling pathway component Jak116 (Fig. 3C,D). The IC50 
values for StA-IFN-1 and -4 are in the µM range, which, 
along with maximum, minimum, and Hill slope values, are 
broadly comparable to TPCA-1 (Fig. 3E).
To eliminate the possibility that StA-IFN-1 and -4 were 
false-positive hits, we demonstrated that these compounds 
did not (1) affect cell viability (Fig. 4A,B), (2) act as inhibi-
tors of global protein synthesis (Fig. 4C), or (3) inhibit SeV 
infection and replication (Fig. 4D). Elimination of com-
pounds with antiviral activity is particularly pertinent to our 
approach, as SeV infection is used to activate the IFN 
induction pathway, and a study using a similar IFNβ  
promoter-driven reporter assay has been used to identify 
flavivirus entry inhibitors.18 In contrast to StA-IFN-1 and 
-4, the five most promising dual-activity hits significantly 
reduced cellular protein synthesis (Suppl. Fig. S4); hence, 
these off-target compounds were not investigated further. 
Figure 1. Single-point high-
throughput screen (HTS) to identify 
compounds that modulate the 
interferon (IFN) induction pathway. 
A single-point HTS was performed 
using the A549/pr(IFNβ).GFP 
reporter assay and Drug Discovery 
Unit (DDU) small diversity set 
(n = 15,667 compounds). (A) A 
schematic of the 384-well plate 
layout; columns 1 to 22 contain a 
single test compound and Sendai 
virus (SeV)–infected cells, column 23 
contains uninfected cells (maximum 
enhanced green fluorescent protein 
[eGFP] inhibition; 100% unactivated), 
and column 24 contains untreated 
SeV-infected cells (baseline eGFP 
inhibition; 0% activated). (B) Screen 
statistics compared with DDU 
preset quality control standards. 
(C) Screen output, represented 
as % effect of eGFP inhibition and 
plotted as a frequency distribution 
of all compounds tested. CV, 
coefficient of variation; S/B, signal-
to-background ratio.
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Overall, the inhibitory effect of StA-IFN-1 and StA-IFN-4 is 
not due to off-target effects, and therefore these compounds are 
likely to specifically inhibit the IFN induction pathway.
Further validation was undertaken by examining com-
pound effect on IFNβ and MxA mRNA levels (Fig. 5). As 
expected, TPCA-1, StA-IFN-1, and StA-IFN-4 signifi-
cantly reduced IFNβ mRNA levels, directly indicating that 
these compounds inhibit the production of IFNβ. The inhib-
itory activity of StA-IFN-1 and -4 is specific to the IFN 
induction pathway, as these compounds had no effect on 
ISG MxA mRNA levels, whereas ruxolitinib, a known 
potent inhibitor of the IFN signaling pathway, significantly 
reduced MxA mRNA levels. These data confirm the inhibi-
tory effect of StA-IFN-1 and -4 on the IFN induction path-
way, independent of the reporter assay used during 
screening.
StA-IFN-4 Inhibits the IFN Induction Pathway at 
or Upstream of IRF3 Phosphorylation
We next instigated studies to determine the mechanism by 
which StA-IFN-1 and StA-IFN-4 target the IFN induction 
pathway. In the first instance, we investigated the IRF3 
branch of the IFN induction pathway by determining if StA-
IFN-1 and StA-IFN-4 block IRF3 nuclear translocation fol-
lowing IFN induction pathway activation via SeV infection 
(Fig. 6A). As expected, IRF3 is primarily cytoplasmic in 
noninfected cells but translocates to the nucleus upon SeV 
infection. Treatment with BX795, a known TBK1 inhibitor 
of the IRF3 branch of the IFN induction pathway,14 or StA-
IFN-4 blocked IRF3 nuclear translocation as IRF3 remained 
predominantly cytoplasmic. In contrast, StA-IFN-1 did not 
affect IRF3 nuclear translocation.
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Figure 2. Secondary hit compound dose-response screening using A549/pr(IFNβ).GFP and A549/pr(ISRE).GFP reporter assays. 
Hit compound secondary screening using a 10-point dose-response curve (twofold dilution series from 50 to 0.1 µM) in the A549/
pr(IFNβ).GFP and A549/pr(ISRE).GFP reporter assays. (A) Plate screen statistics for A549/pr(IFNβ).GFP reporter assays; Drug 
Discovery Unit (DDU) preset quality control standards (dotted lines). (B) pIC50 generated for each hit tested in the A549/pr(IFNβ).
GFP reporter assay. Hits with a pIC50 of 4.3 (IC50 50 µM) were deemed inactive (dotted line). Hits with an IC50 Log(M) ≥5 (IC50 ≤10 
µM) were deemed favorable (dashed line). (C) Plate screen statistics for A549/pr(ISRE).GFP reporter assays; DDU preset quality 
control standards (dotted lines). (D) pIC50 generated for each hit tested in the A549/pr(IFNβ).GFP versus A549/pr(ISRE).GFP 
reporter assay. Boxed hits represent confirmed hit compounds that specifically inhibit the interferon (IFN) induction pathway and have 
a pIC50 ≥5 (IC50 ≤10 µM). Dose-response curves, pIC50 values, and statistics were generated using ActivityBase XE software (IDBS, 
Alameda, CA). S/B, signal-to-background ratio.
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We next demonstrated that StA-IFN-4 resulted in a dra-
matic reduction in phosphorylated IRF3 levels (Fig. 6B,C). 
StA-IFN-1 also caused a moderate reduction in pIRF3 lev-
els. To eliminate the possibility that StA-IFN-4 is acting as 
a global phosphorylation inhibitor, we examined phosphor-
ylated STAT1 (pSTAT1) levels. STAT1 is phosphorylated 
by the Jak1 kinase to activate the IFN signaling pathway.1 
Following activation of the IFN signaling pathway, Jak1 
inhibitor ruxolitinib significantly reduced the levels of 
pSTAT1, whereas StA-IFN-1 and -4 had no impact (Fig. 
6D,E). Overall, these data suggest that StA-IFN-4 targets 
the IRF3 branch of the IFN induction pathway at or upstream 
of IRF3 phosphorylation.
Discussion
Expression of an eGFP reporter gene under the control of 
the IFNβ promoter following virus infection was used to 
successfully develop and execute a cell-based HTS assay to 
identify novel inhibitors of the IFN induction pathway. The 
assay was miniaturized to a 384-well plate format and per-
formed well as robust Z′ factors of >0.6 were consistently 
achieved. The assay has the capacity to target all compo-
nents that participate in and/or regulate the IRF3 and NF-κB 
branches of the IFN induction pathway. This capacity to 
target multiple points in the signaling pathway provides the 
potential to identify novel compounds that target new or 
unknown pathway components.19 The NF-κB signaling 
pathway has been a major focus of drug discovery efforts, 
as this transcription factor regulates several important phys-
iological processes, including the IFN induction pathway. 
As a consequence, hundreds of inhibitors targeting the 
NF-κB signaling pathway have been identified, some of 
which are available in the clinic.20,21 In contrast, relatively 
few compounds targeting components of the IRF3 branch 
of the IFN induction pathway have been reported. Efforts 
have primarily focused on TBK1/IKKε inhibitors, as these 
kinases play a key role in the IFN response and are also 
reported to be important in the development of certain 
human cancers.14,22–26
In this study, we identified and validated two novel com-
pounds (StA-IFN-1 and StA-IFN-4) that specifically inhibit 
the IFN induction pathway. StA-IFN-4 is active against the 
IRF3 branch of the IFN induction pathway at or upstream of 
IRF3 phosphorylation as StA-IFN-4 dramatically reduced 
pIRF3 levels. In contrast, StA-IFN-1 only modestly reduced 
pIRF3 levels. Therefore, while StA-IFN-1 exhibits some 
activity at or before IRF3 phosphorylation, it may also act 
at another point in the activated pathway. While we have 
not eliminated the possibility that StA-IFN-1 acts down-
stream of IRF3 nuclear translocation, it is more likely that 
StA-IFN-1 also targets the NF-κB branch of the IFN induc-
tion pathway. Searches via SciFinder (Scifinder.cas.org) 
revealed several compounds with ~70% similarity to StA-
IFN-1 that have been described as possible Tyr/Ser/Thr 
kinase inhibitors.27 Therefore, we speculate that StA-IFN-1 
acts as a kinase inhibitor targeting the TBK1/IKKε and/or 
IKKα/IKKβ kinase complexes required for the IRF3 and 
NF-κB pathway branches, respectively. In contrast, StA-
IFN-4 appears to be more novel; 85 molecules shared ≥70% 
similarity with StA-IFN-4, but only four publications/pat-
ents are associated with these molecules, none of which 
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Figure 3. Potency and specificity of 
repurchased hit compounds StA-
IFN-1 and StA-IFN-4. Repurchased 
hit compounds StA-IFN-1 (A) and 
StA-IFN-4 (B) were retested using 
a 9-point dose-response curve 
(twofold serial dilution series from 
25 to 0.1 µM) using A549/pr(IFNβ).
GFP reporter assay and TPCA-1 (C) 
or A549/pr(ISRE).GFP reporter assay 
and ruxolitinib (D). Data represent 
the mean of three independent 
experiments each conducted in 
triplicate; error bars indicate SD. 
(E) A549/pr(IFNβ).GFP reporter 
assay dose-response curve generated 
IC50, maximum, minimum, and Hill 
slope values using Prism 6 software 
(GraphPad Software, La Jolla, CA). 
GFP, green fluorescent protein.
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cell viability via an AlamarBlue assay; translational inhibitor, cyclohexamide (CHX), was used as a control. Data representative of three 
independent experiments, each conducted in quadruplicate, and error bars indicate SD. (C) Effect of StA-IFN-1 and StA-IFN-4 on A549 
cellular protein synthesis; the transcriptional inhibitor, actinomycin D (AMD), was used as a control. A549 cells were treated with compound 
and then radiolabeled. Whole-cell lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and 
visualized by phosphoimager analysis. (D) Effect of StA-IFN-1 and StA-IFN-4 on Sendai virus (SeV) replication. A549 cells were treated with 
compound and infected with SeV. Eighteen hours postinfection, cells were radiolabeled. Whole-cell lysates were separated by SDS-PAGE and 
phosphoimager analysis used to quantitate SeV nucleoprotein (NP) levels. NP band intensity was quantified relative to a host cell protein and 
the DMSO control set at 100%. Data represent the mean of three independent experiments; error bars indicate SD.
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MxA mRNA levels in A549 cells activated with purified interferon α (IFNα) (B). Cells were treated with compound 2 h prior to activation. 
Three hours post-SeV infection and 18 h post-IFNα treatment, total cellular RNA was extracted and reverse transcribed. The resultant 
complementary DNA (cDNA) was used to quantitative PCR amplify either IFNβ or MxA sequences using appropriate primers. Ct values 
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of controls. Data represent the mean of three independent experiments, each conducted in triplicate; error bars indicate SD. Statistical 
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contained any indication relevant to the IFN response. In 
common with other phenotypic screens, further target 
deconvolution is required to determine the molecular target 
and mechanism of action of StA-IFN-1 and StA-IFN-4. 
Target deconvolution can be a substantial and lengthy 
undertaking, and its success may depend on a medicinal 
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Figure 6. Effect of StA-IFN-1 and StA-IFN-4 on the IRF3 branch of the interferon (IFN) induction pathway. (A) Effect of StA-IFN-1, 
StA-IFN-4, and BX795 on IRF3 nuclear translocation in A549 cells infected with Sendai virus (SeV). Cells were treated with compound 
2 h prior to activation. Three hours postinfection, cells were fixed, permeabilized, and probed with anti-pIRF3 antibody, followed 
by Texas Red–conjugated secondary antibody. Cells were visualized with a Nikon Microphot-FXA microscope (Nikon, Surrey, UK; 
40× magnification). (B, C) Effect of StA-IFN-1, StA-IFN-4, and BX795 on pIRF3 levels in A549 cells infected with SeV. Cells were 
treated with compound 2 h prior to activation. Three hours postinfection, cells were lysed and subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE)/Western blot, followed by detection with anti-pIRF3 or anti-actin antibody and 
IRDye680 or IRDye800-conjugated secondary antibody, respectively. Bands were visualized (B) and quantified as % pIRF3 relative 
to actin (C). (D, E) Effect of StA-IFN-1, StA-IFN-4, and ruxolitinib on pSTAT1 levels in A549 cells incubated with IFNα. Cells were 
treated with compound 2 h prior to activation. Fifteen minutes post-IFNα treatment, cells were lysed and subjected to SDS-PAGE/
Western blot, followed by detection with anti-pSTAT1 or anti-actin antibody and horseradish peroxidase (HRP) or IRDye800-
conjugated secondary antibody, respectively. Bands were visualized (D) and quantified as % pSTAT1 relative to actin (E). Statistical 
significance was assessed using the Student’s t test to compare compound treatment with the DMSO plus SeV or IFNα (*p < 0.05,  
**p < 0.0005). Mean values from three independent experiments are presented; error bars indicate SD.
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chemistry campaign to increase compound potency and is 
thus beyond the scope of this article.
Our assay also has the potential to identify compounds 
that enhance IFN production, and such compounds would 
be useful to exploit the antiviral properties of type I IFN.11 
Unfortunately, the screen conducted in this study did not 
yield any validated hit compounds that enhanced IFN pro-
duction. Eighteen compounds with IFN-inducing properties 
have previously been identified in an HTS of 94,398 small 
molecules.11 This work used 293T cells with a firefly lucif-
erase reporter gene under the control of the IFNβ promoter, 
and like our assay, the IFN induction pathway was activated 
via SeV (Cantell) infection. However, the authors exclu-
sively looked for IFN inducers, and so inhibitors of the 
IFN induction pathway were not reported. A notable differ-
ence between these IFNβ promoter assays using different 
reporter genes was the S/B ratio. Our eGFP-based assay 
typically achieved a low S/B ratio of 3, whereas the lucifer-
ase-based screen achieved a significantly higher S/B ratio 
of 11,934.61.11 While a high S/B ratio is preferable in assay 
development, the importance of this parameter is overrid-
den by an excellent Z′ factor score, which better indicates 
assay quality as it takes into account both the assay signal 
window (S/B ratio) and data variability.17 Despite the rela-
tively low S/B ratio attained in our assay, we consistently 
achieved a robust Z′ factor of >0.6, which indicated an 
excellent assay suitable for HTS. In addition, we choose 
to use an eGFP reporter gene because luciferase-based 
reporter gene assays are prone to compound interference.28 
Nevertheless, the success of these screens validates this 
HTS approach as a strategy to discover small molecules that 
modulate the IFN response. In addition, we propose that the 
validation of our A549/pr(IFNβ).GFP and A549/pr(ISRE).
GFP reporter cell lines permits them to be used as a plat-
form to target viral IFN antagonists to discover novel anti-
viral compounds.
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